drugset / Trial / NCT01099644

Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum

NCT01099644

Phase 1 Terminated 54 enrolled Y-mAbs Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

A phase I study of Intraperitoneal Radioimmunotherapy with 131 I-omburtamab in patients \>1 year of age with desmoplastic small round cell tumors and other solid tumors involving the peritoneum.

Timeline

Start
2010-04
Primary completion
2019-06-11
Completion
2019-06-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Omburtamab Monoclonal antibody 1110 mbq Other
Subject Omburtamab Monoclonal antibody 2960 mbq Other
Subject Omburtamab Monoclonal antibody 3330 mbq Other

Indications